1
|
He Y, Gong F, Jin T, Liu Q, Fang H, Chen Y, Wang G, Chu PK, Wu Z, Ostrikov K(K. Dose-Dependent Effects in Plasma Oncotherapy: Critical In Vivo Immune Responses Missed by In Vitro Studies. Biomolecules 2023; 13:707. [PMID: 37189453 PMCID: PMC10136314 DOI: 10.3390/biom13040707] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/09/2023] [Revised: 03/21/2023] [Accepted: 04/17/2023] [Indexed: 05/17/2023] Open
Abstract
Cold atmospheric plasma (CAP) generates abundant reactive oxygen and nitrogen species (ROS and RNS, respectively) which can induce apoptosis, necrosis, and other biological responses in tumor cells. However, the frequently observed different biological responses to in vitro and in vivo CAP treatments remain poorly understood. Here, we reveal and explain plasma-generated ROS/RNS doses and immune system-related responses in a focused case study of the interactions of CAP with colon cancer cells in vitro and with the corresponding tumor in vivo. Plasma controls the biological activities of MC38 murine colon cancer cells and the involved tumor-infiltrating lymphocytes (TILs). In vitro CAP treatment causes necrosis and apoptosis in MC38 cells, which is dependent on the generated doses of intracellular and extracellular ROS/RNS. However, in vivo CAP treatment for 14 days decreases the proportion and number of tumor-infiltrating CD8+T cells while increasing PD-L1 and PD-1 expression in the tumors and the TILs, which promotes tumor growth in the studied C57BL/6 mice. Furthermore, the ROS/RNS levels in the tumor interstitial fluid of the CAP-treated mice are significantly lower than those in the MC38 cell culture supernatant. The results indicate that low doses of ROS/RNS derived from in vivo CAP treatment may activate the PD-1/PD-L1 signaling pathway in the tumor microenvironment and lead to the undesired tumor immune escape. Collectively, these results suggest the crucial role of the effect of doses of plasma-generated ROS and RNS, which are generally different in in vitro and in vivo treatments, and also suggest that appropriate dose adjustments are required upon translation to real-world plasma oncotherapy.
Collapse
Affiliation(s)
- Yuanyuan He
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
- Department of Geriatrics, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, China
| | - Fanwu Gong
- Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, China
| | - Tao Jin
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
| | - Qi Liu
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
| | - Haopeng Fang
- Department of Medical Oncology, Division of Life Sciences and Medicine, The First Affiliated Hospital of USTC, University of Science and Technology of China, Hefei 230001, China
| | - Yan Chen
- Joint Laboratory of Plasma Application Technology, Institute of Advanced Technology, University of Science and Technology of China, Hefei 230026, China
| | - Guomin Wang
- Department of Orthopedics, School of Medicine, Shanghai Tenth People’s Hospital, Tongji University, Shanghai 200072, China
- Department of Physics, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong 999077, China
| | - Paul K. Chu
- Department of Physics, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong 999077, China
- Department of Materials Science and Engineering, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong 999077, China
- Department of Biomedical Engineering, City University of Hong Kong, Tat Chee Avenue, Kowloon, Hong Kong 999077, China
| | - Zhengwei Wu
- School of Nuclear Science and Technology, University of Science and Technology of China, Hefei 230026, China
- Joint Laboratory of Plasma Application Technology, Institute of Advanced Technology, University of Science and Technology of China, Hefei 230026, China
| | - Kostya (Ken) Ostrikov
- School of Chemistry and Physics and QUT Centre for Biomedical Technologies, Queensland University of Technology (QUT), Brisbane, QLD 4000, Australia
| |
Collapse
|
2
|
Clemen R, Arlt K, von Woedtke T, Bekeschus S. Gas Plasma Protein Oxidation Increases Immunogenicity and Human Antigen-Presenting Cell Maturation and Activation. Vaccines (Basel) 2022; 10:1814. [PMID: 36366323 PMCID: PMC9698879 DOI: 10.3390/vaccines10111814] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/12/2022] [Revised: 10/24/2022] [Accepted: 10/24/2022] [Indexed: 08/06/2023] Open
Abstract
Protein vaccines rely on eliciting immune responses. Inflammation is a prerequisite for immune responses to control infection and cancer but is also associated with disease onset. Reactive oxygen species (ROSs) are central during inflammation and are capable of inducing non-enzymatic oxidative protein modifications (oxMods) associated with chronic disease, which alter the functionality or immunogenicity of proteins that are relevant in cancer immunotherapy. Specifically, antigen-presenting cells (APCs) take up and degrade extracellular native and oxidized proteins to induce adaptive immune responses. However, it is less clear how oxMods alter the protein's immunogenicity, especially in inflammation-related short-lived reactive species. Gas plasma technology simultaneously generates a multitude of ROSs to modify protein antigens in a targeted and controlled manner to study the immunogenicity of oxMods. As model proteins relevant to chronic inflammation and cancer, we used gas plasma-treated insulin and CXCL8. We added those native or oxidized proteins to human THP-1 monocytes or primary monocyte-derived cells (moDCs). Both oxidized proteins caused concentration-independent maturation phenotype alterations in moDCs and THP-1 cells concerning surface marker expression and chemokine and cytokine secretion profiles. Interestingly, concentration-matched H2O2-treated proteins did not recapitulate the effects of gas plasma, suggesting sufficiently short diffusion distances for the short-lived reactive species to modify proteins. Our data provide evidence of dendric cell maturation and activation upon exposure to gas plasma- but not H2O2-modified model proteins. The biological consequences of these findings need to be elucidated in future inflammation and cancer disease models.
Collapse
|
3
|
Trzeciak ER, Zimmer N, Gehringer I, Stein L, Graefen B, Schupp J, Stephan A, Rietz S, Prantner M, Tuettenberg A. Oxidative Stress Differentially Influences the Survival and Metabolism of Cells in the Melanoma Microenvironment. Cells 2022; 11:cells11060930. [PMID: 35326381 PMCID: PMC8946823 DOI: 10.3390/cells11060930] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/31/2022] [Revised: 03/03/2022] [Accepted: 03/05/2022] [Indexed: 12/12/2022] Open
Abstract
The cellular composition of the tumor microenvironment, including tumor, immune, stromal, and endothelial cells, significantly influences responses to cancer therapies. In this study, we analyzed the impact of oxidative stress, induced by cold atmospheric plasma (CAP), on tumor cells, T cells, and macrophages, which comprise part of the melanoma microenvironment. To accomplish this, cells were grown in different in vitro cell culture models and were treated with varying amounts of CAP. Subsequent alterations in viability, proliferation, and phenotype were analyzed via flow cytometry and metabolic alterations by Seahorse Cell Mito Stress Tests. It was found that cells generally exhibited reduced viability and proliferation, stemming from CAP induced G2/M cell cycle arrest and subsequent apoptosis, as well as increased mitochondrial stress following CAP treatment. Overall, sensitivity to CAP treatment was found to be cell type dependent with T cells being the most affected. Interestingly, CAP influenced the polarization of M0 macrophages to a "M0/M2-like" phenotype, and M1 macrophages were found to display a heightened sensitivity to CAP induced mitochondrial stress. CAP also inhibited the growth and killed melanoma cells in 2D and 3D in vitro cell culture models in a dose-dependent manner. Improving our understanding of oxidative stress, mechanisms to manipulate it, and its implications for the tumor microenvironment may help in the discovery of new therapeutic targets.
Collapse
Affiliation(s)
- Emily R. Trzeciak
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
| | - Niklas Zimmer
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
| | - Isabelle Gehringer
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
| | - Lara Stein
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
- Institute of Immunology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
| | - Barbara Graefen
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
| | - Jonathan Schupp
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
- Institute of Neurology (Edinger Institute), Goethe University Hospital Frankfurt, 60528 Frankfurt, Germany
- Frankfurt Cancer Institute, 60596 Frankfurt, Germany
| | - Achim Stephan
- BOWA-Electronic GmbH & Co. KG, 72810 Gomaringen, Germany; (A.S.); (M.P.)
| | - Stephan Rietz
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
| | - Michael Prantner
- BOWA-Electronic GmbH & Co. KG, 72810 Gomaringen, Germany; (A.S.); (M.P.)
| | - Andrea Tuettenberg
- Department of Dermatology, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany; (E.R.T.); (N.Z.); (I.G.); (L.S.); (B.G.); (J.S.); (S.R.)
- Research Center for Immunotherapy, University Medical Center Mainz, Johannes Gutenberg University Mainz, 55131 Mainz, Germany
- Correspondence:
| |
Collapse
|
4
|
Cold Physical Plasma in Cancer Therapy: Mechanisms, Signaling, and Immunity. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2021; 2021:9916796. [PMID: 35284036 PMCID: PMC8906949 DOI: 10.1155/2021/9916796] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/22/2021] [Accepted: 11/26/2021] [Indexed: 12/11/2022]
Abstract
Despite recent advances in therapy, cancer still is a devastating and life-threatening disease, motivating novel research lines in oncology. Cold physical plasma, a partially ionized gas, is a new modality in cancer research. Physical plasma produces various physicochemical factors, primarily reactive oxygen and nitrogen species (ROS/RNS), causing cancer cell death when supplied at supraphysiological concentrations. This review outlines the biomedical consequences of plasma treatment in experimental cancer therapy, including cell death modalities. It also summarizes current knowledge on intracellular signaling pathways triggered by plasma treatment to induce cancer cell death. Besides the inactivation of tumor cells, an equally important aspect is the inflammatory context in which cell death occurs to suppress or promote the responses of immune cells. This is mainly governed by the release of damage-associated molecular patterns (DAMPs) to provoke immunogenic cancer cell death (ICD) that, in turn, activates cells of the innate immune system to promote adaptive antitumor immunity. The pivotal role of the immune system in cancer treatment, in general, is highlighted by many clinical trials and success stories on using checkpoint immunotherapy. Hence, the potential of plasma treatment to induce ICD in tumor cells to promote immunity targeting cancer lesions systemically is also discussed.
Collapse
|
5
|
Tan F, Rui X, Xiang X, Yu Z, Al-Rubeai M. Multimodal treatment combining cold atmospheric plasma and acidic fibroblast growth factor for multi-tissue regeneration. FASEB J 2021; 35:e21442. [PMID: 33774850 DOI: 10.1096/fj.202002611r] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/02/2020] [Revised: 01/21/2021] [Accepted: 01/29/2021] [Indexed: 02/07/2023]
Abstract
Cold atmospheric plasma (CAP) is an emerging technology for biomedical applications, exemplified by its antimicrobial and antineoplastic potentials. On the contrary, acidic fibroblast growth factor (aFGF) has been a long-standing potent mitogen for cells from various origins. In this study, we are the first to develop a multimodal treatment combining the aforementioned physicochemical and pharmacological treatments and investigated their individual and combined effects on wound healing, angiogenesis, neurogenesis, and osteogenesis. This work was performed at the tissue, cellular, protein, and gene levels, using histochemical staining, flow cytometry, ELISA, and PCR, respectively. Depending on the type of target tissue, various combinations of aforementioned methods were used. The results showed that the enhancement on would healing and angiogenesis by CAP and aFGF were synergistic. The former was manifested by increased murine fibroblast proliferation and reduced cutaneous tissue inflammation, whereas the latter by upregulated proangiogenic markers in vivo, for example, CD31, VEGF, and TGF-β, and downregulated antiangiogenic proteins in vitro, for example, angiostatin and angiopoietin-2, respectively. In addition, aFGF outperformed CAP during neurogenesis, which was evidenced by superior neurite outgrowth, while CAP exceeded aFGF in osteogenesis which was demonstrated by more substantial bone nodule formation. These novel findings not only support the fact that CAP and aFGF are both multipotent agents during tissue regeneration, but also highlight the potential of our multimodal treatment combining the individual advantages of CAP and aFGF. The versatile administration route, that is, topical and/or systemic, might further broaden its applications.
Collapse
Affiliation(s)
- Fei Tan
- Department of ORL-HNS, Shanghai East Hospital, Shanghai, China.,School of Medicine, Tongji University, Shanghai, China.,The Royal College of Surgeons of England, London, UK
| | - Xiaoqing Rui
- Department of ORL-HNS, Shanghai East Hospital, Shanghai, China
| | - Xue Xiang
- Research Center for Translational Medicine, Shanghai East Hospital, Shanghai, China
| | - Zuoren Yu
- School of Medicine, Tongji University, Shanghai, China.,Research Center for Translational Medicine, Shanghai East Hospital, Shanghai, China
| | - Mohamed Al-Rubeai
- Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
| |
Collapse
|
6
|
Smolková B, Frtús A, Uzhytchak M, Lunova M, Kubinová Š, Dejneka A, Lunov O. Critical Analysis of Non-Thermal Plasma-Driven Modulation of Immune Cells from Clinical Perspective. Int J Mol Sci 2020; 21:ijms21176226. [PMID: 32872159 PMCID: PMC7503900 DOI: 10.3390/ijms21176226] [Citation(s) in RCA: 12] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/10/2020] [Revised: 07/30/2020] [Accepted: 08/26/2020] [Indexed: 02/07/2023] Open
Abstract
The emerged field of non-thermal plasma (NTP) shows great potential in the alteration of cell redox status, which can be utilized as a promising therapeutic implication. In recent years, the NTP field considerably progresses in the modulation of immune cell function leading to promising in vivo results. In fact, understanding the underlying cellular mechanisms triggered by NTP remains incomplete. In order to boost the field closer to real-life clinical applications, there is a need for a critical overview of the current state-of-the-art. In this review, we conduct a critical analysis of the NTP-triggered modulation of immune cells. Importantly, we analyze pitfalls in the field and identify persisting challenges. We show that the identification of misconceptions opens a door to the development of a research strategy to overcome these limitations. Finally, we propose the idea that solving problems highlighted in this review will accelerate the clinical translation of NTP-based treatments.
Collapse
Affiliation(s)
- Barbora Smolková
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
| | - Adam Frtús
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
| | - Mariia Uzhytchak
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
| | - Mariia Lunova
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
- Institute for Clinical & Experimental Medicine (IKEM), 14021 Prague, Czech Republic
| | - Šárka Kubinová
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
- Department of Biomaterials and Biophysical Methods, Institute of Experimental Medicine of the Czech Academy of Sciences, 14220 Prague, Czech Republic
| | - Alexandr Dejneka
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
| | - Oleg Lunov
- Department of Optical and Biophysical Systems, Institute of Physics of the Czech Academy of Sciences, 18221 Prague, Czech Republic; (B.S.); (A.F.); (M.U.); (M.L.); (Š.K.); (A.D.)
- Correspondence: ; Tel.: +420-2660-52131
| |
Collapse
|
7
|
Abstract
For many decades non-equilibrium plasmas (NEPs) that can be generated at atmospheric pressure have played important roles in various material and surface processing applications [...]
Collapse
|
8
|
Bisag A, Bucci C, Coluccelli S, Girolimetti G, Laurita R, De Iaco P, Perrone AM, Gherardi M, Marchio L, Porcelli AM, Colombo V, Gasparre G. Plasma-activated Ringer's Lactate Solution Displays a Selective Cytotoxic Effect on Ovarian Cancer Cells. Cancers (Basel) 2020; 12:cancers12020476. [PMID: 32085609 PMCID: PMC7072540 DOI: 10.3390/cancers12020476] [Citation(s) in RCA: 23] [Impact Index Per Article: 5.8] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2019] [Revised: 02/13/2020] [Accepted: 02/17/2020] [Indexed: 12/20/2022] Open
Abstract
Epithelial Ovarian Cancer (EOC) is one of the leading causes of cancer-related deaths among women and is characterized by the diffusion of nodules or plaques from the ovary to the peritoneal surfaces. Conventional therapeutic options cannot eradicate the disease and show low efficacy against resistant tumor subclones. The treatment of liquids via cold atmospheric pressure plasma enables the production of plasma-activated liquids (PALs) containing reactive oxygen and nitrogen species (RONS) with selective anticancer activity. Thus, the delivery of RONS to cancer tissues by intraperitoneal washing with PALs might be an innovative strategy for the treatment of EOC. In this work, plasma-activated Ringer’s Lactate solution (PA-RL) was produced by exposing a liquid substrate to a multiwire plasma source. Subsequently, PA-RL dilutions are used for the treatment of EOC, non-cancer and fibroblast cell lines, revealing a selectivity of PA-RL, which induces a significantly higher cytotoxic effect in EOC with respect to non-cancer cells.
Collapse
Affiliation(s)
- Alina Bisag
- Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy; (A.B.); (C.B.); (S.C.); (M.G.); (V.C.)
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
| | - Cristiana Bucci
- Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy; (A.B.); (C.B.); (S.C.); (M.G.); (V.C.)
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy
| | - Sara Coluccelli
- Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy; (A.B.); (C.B.); (S.C.); (M.G.); (V.C.)
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Unit of Gynecologic Oncology, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy
- Center for Applied Biomedical Research, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
| | - Giulia Girolimetti
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Center for Applied Biomedical Research, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Correspondence: (G.G.); (R.L.)
| | - Romolo Laurita
- Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy; (A.B.); (C.B.); (S.C.); (M.G.); (V.C.)
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Interdepartmental Center for Industrial Research Advanced Mechanical Engineering Applications and Materials Technology, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy
- Correspondence: (G.G.); (R.L.)
| | - Pierandrea De Iaco
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Unit of Gynecologic Oncology, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy
| | - Anna Myriam Perrone
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Unit of Gynecologic Oncology, S. Orsola-Malpighi Hospital, 40138 Bologna, Italy
| | - Matteo Gherardi
- Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy; (A.B.); (C.B.); (S.C.); (M.G.); (V.C.)
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Interdepartmental Center for Industrial Research Advanced Mechanical Engineering Applications and Materials Technology, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy
| | - Lorena Marchio
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Center for Applied Biomedical Research, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
| | - Anna Maria Porcelli
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Pharmacy and Biotechnology, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy
- Interdepartmental Center for Industrial Research Life Sciences and Technologies for Health, Alma Mater Studiorum-University of Bologna, 40064 Ozzano dell’Emilia, Italy
| | - Vittorio Colombo
- Department of Industrial Engineering, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy; (A.B.); (C.B.); (S.C.); (M.G.); (V.C.)
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Interdepartmental Center for Industrial Research Advanced Mechanical Engineering Applications and Materials Technology, Alma Mater Studiorum-University of Bologna, 40136 Bologna, Italy
- Interdepartmental Center for Industrial Research Agrifood, Alma Mater Studiorum-University of Bologna, 40126 Bologna, Italy
| | - Giuseppe Gasparre
- Centro di Studio e Ricerca sulle Neoplasie Ginecologiche, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy; (P.D.I.); (A.M.P.); (L.M.); (A.M.P.)
- Department of Medical and Surgical Sciences, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
- Center for Applied Biomedical Research, Alma Mater Studiorum-University of Bologna, 40138 Bologna, Italy
| |
Collapse
|
9
|
ROS from Physical Plasmas: Redox Chemistry for Biomedical Therapy. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2019; 2019:9062098. [PMID: 31687089 PMCID: PMC6800937 DOI: 10.1155/2019/9062098] [Citation(s) in RCA: 117] [Impact Index Per Article: 23.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 05/10/2019] [Revised: 07/17/2019] [Accepted: 08/25/2019] [Indexed: 12/24/2022]
Abstract
Physical plasmas generate unique mixes of reactive oxygen and nitrogen species (RONS or ROS). Only a bit more than a decade ago, these plasmas, operating at body temperature, started to be considered for medical therapy with considerably little mechanistic redox chemistry or biomedical research existing on that topic at that time. Today, a vast body of evidence is available on physical plasma-derived ROS, from their spatiotemporal resolution in the plasma gas phase to sophisticated chemical and biochemical analysis of these species once dissolved in liquids. Data from in silico analysis dissected potential reaction pathways of plasma-derived reactive species with biological membranes, and in vitro and in vivo experiments in cell and animal disease models identified molecular mechanisms and potential therapeutic benefits of physical plasmas. In 2013, the first medical plasma systems entered the European market as class IIa devices and have proven to be a valuable resource in dermatology, especially for supporting the healing of chronic wounds. The first results in cancer patients treated with plasma are promising, too. Due to the many potentials of this blooming new field ahead, there is a need to highlight the main concepts distilled from plasma research in chemistry and biology that serve as a mechanistic link between plasma physics (how and which plasma-derived ROS are produced) and therapy (what is the medical benefit). This inevitably puts cellular membranes in focus, as these are the natural interphase between ROS produced by plasmas and translation of their chemical reactivity into distinct biological responses.
Collapse
|